996 related articles for article (PubMed ID: 15918297)
41. Specific IgE response before and after rush immunotherapy with a standardized allergen or allergoid in grass pollen allergy.
Bousquet J; Braquemond P; Feinberg J; Guerin B; Maasch H; Michel FB
Ann Allergy; 1986 Jun; 56(6):456-9. PubMed ID: 3717711
[TBL] [Abstract][Full Text] [Related]
42. Immunotherapy with sublingual birch pollen extract. A short-term double-blind placebo study.
Horak F; Stübner P; Berger UE; Marks B; Toth J; Jäger S
J Investig Allergol Clin Immunol; 1998; 8(3):165-71. PubMed ID: 9684190
[TBL] [Abstract][Full Text] [Related]
43. [Juniperus ashei: the gold standard of the Cuppressaceae].
André C; Dumur JP; Hrabina M; Lefebvre E; Sicard H
Allerg Immunol (Paris); 2000 Mar; 32(3):104-6. PubMed ID: 10815237
[TBL] [Abstract][Full Text] [Related]
44. Juniperus oxycedrus: a new allergenic pollen from the Cupressaceae family.
Iacovacci P; Afferni C; Barletta B; Tinghino R; Di Felice G; Pini C; Mari A
J Allergy Clin Immunol; 1998 Jun; 101(6 Pt 1):755-61. PubMed ID: 9648702
[TBL] [Abstract][Full Text] [Related]
45. A prospective, randomized, double-blind, placebo-controlled multi-centre study on the efficacy and safety of sublingual immunotherapy (SLIT) in children with seasonal allergic rhinoconjunctivitis to grass pollen.
Rolinck-Werninghaus C; Wolf H; Liebke C; Baars JC; Lange J; Kopp MV; Hammermann J; Leupold W; Bartels P; Gruebl A; Bauer CP; Schnitker J; Wahn U; Niggemann B
Allergy; 2004 Dec; 59(12):1285-93. PubMed ID: 15507097
[TBL] [Abstract][Full Text] [Related]
46. [Vaccination with allergens in children].
Demoly P; Dhivert-Donnadieu H; Bousquet J
Allerg Immunol (Paris); 2000 Dec; 32(10):397-401. PubMed ID: 11209473
[TBL] [Abstract][Full Text] [Related]
47. [Allergy to cypress pollen: preparation of a reference and standardization extract in vivo].
Leduc V; Charpin D; Aparicio C; Veber C; Guérin L
Allerg Immunol (Paris); 2000 Mar; 32(3):101-3. PubMed ID: 10815236
[TBL] [Abstract][Full Text] [Related]
48. The effects of short-term immunotherapy using molecular standardized grass and rye allergens compared with symptomatic drug treatment on rhinoconjunctivitis symptoms, skin sensitivity, and specific nasal reactivity.
Klimek L; Mewes T; Wolf H; Hansen I; Schnitker J; Mann WJ
Otolaryngol Head Neck Surg; 2005 Oct; 133(4):538-43. PubMed ID: 16213926
[TBL] [Abstract][Full Text] [Related]
49. Safety of sublingual immunotherapy with a monomeric allergoid in very young children.
Agostinis F; Tellarini L; Canonica GW; Falagiani P; Passalacqua G
Allergy; 2005 Jan; 60(1):133. PubMed ID: 15575951
[No Abstract] [Full Text] [Related]
50. Efficacy and safety of specific immunotherapy to mosquito bites.
Ariano R; Panzani RC
Eur Ann Allergy Clin Immunol; 2004 Apr; 36(4):131-8. PubMed ID: 15180354
[TBL] [Abstract][Full Text] [Related]
51. Efficacy and safety of subcutaneous immunotherapy with a biologically standardized extract of Ambrosia artemisiifolia pollen: a double-blind, placebo-controlled study.
Mirone C; Albert F; Tosi A; Mocchetti F; Mosca S; Giorgino M; Pecora S; Parmiani S; Ortolani C
Clin Exp Allergy; 2004 Sep; 34(9):1408-14. PubMed ID: 15347374
[TBL] [Abstract][Full Text] [Related]
52. Sublingual immunotherapy with Dermatophagoides monomeric allergoid down-regulates allergen-specific immunoglobulin E and increases both interferon-gamma- and interleukin-10-production.
Cosmi L; Santarlasci V; Angeli R; Liotta F; Maggi L; Frosali F; Rossi O; Falagiani P; Riva G; Romagnani S; Annunziato F; Maggi E
Clin Exp Allergy; 2006 Mar; 36(3):261-72. PubMed ID: 16499636
[TBL] [Abstract][Full Text] [Related]
53. Intradermal Phleum pratense allergoid immunotherapy. Double-blind, randomized, placebo-controlled trial.
Sola Martínez FJ; Barranco Jiménez RM; Martín García C; Senent Sánchez C; Blanco Guerra C; Fernández-Rivas M; Vega Castro A; Dávila González I; Carbonell Martínez A; Panizo Bravo C; Gómez Torrijos E; Rodríguez Gil D; Palacios Peláez R
Clin Exp Allergy; 2020 Dec; 50(12):1352-1361. PubMed ID: 32946612
[TBL] [Abstract][Full Text] [Related]
54. Preseasonal local allergoid immunotherapy to grass pollen in children: a double-blind, placebo-controlled, randomized trial.
Caffarelli C; Sensi LG; Marcucci F; Cavagni G
Allergy; 2000 Dec; 55(12):1142-7. PubMed ID: 11117271
[TBL] [Abstract][Full Text] [Related]
55. Effect of sublingual immunotherapy with grass monomeric allergoid on allergen-specific T-cell proliferation and interleukin 10 production.
Burastero SE; Mistrello G; Falagiani P; Paolucci C; Breda D; Roncarolo D; Zanotta S; Monasterolo G; Rossi RE
Ann Allergy Asthma Immunol; 2008 Apr; 100(4):343-50. PubMed ID: 18450120
[TBL] [Abstract][Full Text] [Related]
56. Sublingual-oral administration of standardized allergenic extracts: phase 1 safety and dosing results.
Esch RE; Bush RK; Peden D; Lockey RF
Ann Allergy Asthma Immunol; 2008 May; 100(5):475-81. PubMed ID: 18517081
[TBL] [Abstract][Full Text] [Related]
57. The efficacy of E.P.D., a new immunotherapy, in the treatment of allergic diseases in children.
Caramia G; Franceschini F; Cimarelli ZA; Ciucchi MS; Gagliardini R; Ruffini E
Allerg Immunol (Paris); 1996 Nov; 28(9):308-10. PubMed ID: 8986246
[TBL] [Abstract][Full Text] [Related]
58. Oral allergy syndrome in patients with airborne pollen allergy treated with specific immunotherapy.
Czarnecka-Operacz M; Jenerowicz D; Silny W
Acta Dermatovenerol Croat; 2008; 16(1):19-24. PubMed ID: 18358104
[TBL] [Abstract][Full Text] [Related]
59. Cluster immunotherapy with a glutaraldehyde-modified mixture of grasses results in an improvement in specific nasal provocation tests in less than 2.5 months of treatment.
Subiza J; Feliú A; Subiza JL; Uhlig J; Fernández-Caldas E
Clin Exp Allergy; 2008 Jun; 38(6):987-94. PubMed ID: 18445082
[TBL] [Abstract][Full Text] [Related]
60. Long-term efficacy of sublingual immunotherapy in patients with perennial rhinitis.
Tahamiler R; Saritzali G; Canakcioglu S
Laryngoscope; 2007 Jun; 117(6):965-9. PubMed ID: 17545861
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
